Solamargine inhibits the growth of hepatocellular carcinoma and enhances the anticancer effect of sorafenib by regulating HOTTIP‐TUG1/miR‐4726‐5p/MUC1 pathway

Hepatocellular carcinoma (HCC) is one of the most common primary malignancies. Drug resistance has significantly prevented the clinical application of sorafenib (SF), a first‐line targeted medicine for the treatment of HCC. Solamargine (SM), a natural alkaloid, has shown potential antitumor activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Qing, Li, Xiaojuan, Chen, Yun, Long, Shunqin, Yu, Yaya, Sheng, Honghao, Wang, Sumei, Han, Ling, Wu, Wanyin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302658/
https://www.ncbi.nlm.nih.gov/pubmed/35040191
http://dx.doi.org/10.1002/mc.23389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302658/
https://www.ncbi.nlm.nih.gov/pubmed/35040191
http://dx.doi.org/10.1002/mc.23389

Ejemplares similares